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Despite tremendous advances in diagnostic laboratory technology, identifying the pathogen(s) causing pneumonia remains chal-
lenging because the infected lung tissue cannot usually be sampled for testing. Consequently, to obtain information about pneu-
monia etiology, clinicians and researchers test specimens distant to the site of infection. These tests may lack sensitivity (eg, blood 
culture, which is only positive in a small proportion of children with pneumonia) and/or specificity (eg, detection of pathogens in 
upper respiratory tract specimens, which may indicate asymptomatic carriage or a less severe syndrome, such as upper respiratory 
infection). While highly sensitive nucleic acid detection methods and testing of multiple specimens improve sensitivity, multiple 
pathogens are often detected and this adds complexity to the interpretation as the etiologic significance of results may be unclear (ie, 
the pneumonia may be caused by none, one, some, or all of the pathogens detected). Some of these challenges can be addressed by 
adjusting positivity rates to account for poor sensitivity or incorporating test results from controls without pneumonia to account 
for poor specificity. However, no classical analytic methods can account for measurement error (ie, sensitivity and specificity) for 
multiple specimen types and integrate the results of measurements for multiple pathogens to produce an accurate understanding 
of etiology. We describe the major analytic challenges in determining pneumonia etiology and review how the common analytical 
approaches (eg, descriptive, case-control, attributable fraction, latent class analysis) address some but not all challenges. We demon-
strate how these limitations necessitate a new, integrated analytical approach to pneumonia etiology data.
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Many an object is not seen, though it falls within the range 
of our visual ray, because it does not come within the range 
of our intellectual ray, i.e. we are not looking for it. So, in the 
largest sense, we find only the world we look for.
—Henry David Thoreau, Journal, 2 July 1857
Investigation of the etiology of childhood pneumonia has long 
guided targeted prevention and treatment strategies. As the dis-
eased tissue (ie, the lung) is not routinely sampled for testing 
[1], pneumonia etiology is typically inferred using test results 
of specimens from other anatomical sites. In the traditional 
approach to pneumonia etiology, detection of pathogens has 
been synonymous with causation, without fully accounting for 
the limitations of the testing methods.
For tests with low sensitivity (eg, blood culture for bacteria), 
researchers can accept these imperfect results as “conservative 
estimates” of a pathogen’s role. Tests with exquisite analytical 
sensitivity (ie, ability to detect presence of a pathogen in a spec-
imen) will detect a pathogen in the upper respiratory tract of 
the vast majority of children with pneumonia and many will 
test positive for >1 pathogen. However, use of an increas-
ing number of imperfectly specific tests results in a trade-off 
between diagnostic yield and diagnostic accuracy and adds 
complexity when combining and interpreting the results of 
these tests.
With the goal of improving the way we use available data to 
understand the etiology of pneumonia, we describe key analytic 
challenges and the existing analytic approaches that only par-
tially address them (Table 1), and illustrate how the approach to 
analysis influences etiologic inferences.
Challenge 1: Imperfect Diagnostic Sensitivity of Assays
Historically, pediatric pneumonia etiology studies usually only 
described clinical and microbiological findings in a series of 
cases. In studies relying on culture of sterile-site specimens (eg, 
blood, pleural fluid), pneumonia is attributed to the cultured 
pathogen. However, the sensitivity of blood culture is poor for 
detecting bacterial pneumonia, both because bacteremia in true 
cases of bacterial pneumonia is uncommon or intermittent and 
because of antibiotic effects [2].
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Approach to Challenge 1: Adjust for Test Diagnostic Sensitivity
We can account for the poor sensitivity of blood culture for 
detection of pneumonia etiology by multiplying the propor-
tion positive by the reciprocal of the sensitivity. For exam-
ple, if 36 of 1000 (3.6%) children had positive blood cultures 
(Figure  1, method A), adjusting for a sensitivity of 10% 
would imply that 360 (36%) cases are attributable to those 
identified bacteria (Figure  1, method B). However, there is 
no information to guide which specific 324 additional chil-
dren (360 assumed positive minus 36 test positive) with “false 
negative” blood cultures should be attributed to a bacterial 
etiology following the sensitivity adjustment since the sensi-
tivity adjustment can be applied at the population level but 
not to individual patients. Another challenge is obtaining an 
accurate estimate of the sensitivity to use for this adjustment. 
For some bacterial species (eg, pneumococcus, Haemophilus 
influenzae type b), we can estimate the sensitivity of blood 
culture directly using lung aspirate studies or indirectly 
using vaccine probe studies by comparing the incidence of 
bacteremic pneumonia prevented relative to the incidence of 
all clinical pneumonia prevented. Unfortunately, empirical 
data are lacking for most bacterial species, which do not have 
effective vaccines to be used as probes, and sensitivity can 
also vary depending on antibiotic exposure prior to speci-
men collection.
Challenge 2: Imperfect Diagnostic Specificity of Assays
Although nucleic acid detection tests (eg, polymerase chain 
reaction [PCR]) have very high specificity for the detection 
of respiratory pathogens in the specimen, these measurements 
have imperfect diagnostic specificity for determining the eti-
ology of pneumonia. A  respiratory virus can be detected in 
the nasopharynx of 25%–80% of children hospitalized with 
pneumonia, but many of these respiratory viruses are detected 
nearly as frequently in healthy children or children with upper 
respiratory tract infection but without pneumonia, making 
the etiologic significance of the results unclear [3–10]. Even 
the diagnostic specificity of tests of sterile-site specimens is 
imperfect. For example, presence of gram-negative rods in the 
blood of pneumonia cases with malnutrition and sepsis may not 
indicate the cause of the pneumonia, but merely that the integ-
rity of the bowel wall is compromised in severely ill children. 
Furthermore, evidence indicates that the healthy lung is home to 
a diverse community of microbes and that pneumonia develops 
within this ecosystem [11]. Therefore, detection of organisms in 
lung tissue, long thought to be the gold standard assessment of 
pneumonia etiology, also has imperfect specificity.
As additional specimens and tests are incorporated into the 
diagnostic evaluation of children with pneumonia, the propor-
tion in whom a potential pathogen is identified increases, but 
so does the proportion with false-positive results (Figure 2). For 
Table 1. Limitations of Available Analytic Approaches to Address Challenges in Interpreting Data From Cross-Sectional Pneumonia Etiology Studies
Challenge Possible Approaches Limitation of Approaches
Imperfect diagnostic 
sensitivity of  
assays
1. Assume 100% • Underestimates role of pathogen if true sensitivity is <100%
2. Adjust for test sensitivity • Adjustment will increase the number of positives, but it is not possible to attribute etiology to specific 
individuals
• Not possible to integrate adjusted results at an individual level with other results
Imperfect diagnostic 
specificity of  
assays
1. Assume 100% • Overestimates role of pathogen if true specificity is <100%
2. Case-control odds ratio • Cannot be applied to assays not available from controls
• For measurements associated with case status, assumes specificity of measurement in cases is 100%
• Researchers must set rules for interpretation (eg, whether a pathogen will be deemed to be causal if 
the odds ratio is >1 or only if statistically significantly >1). Statistical significance of findings (ie, assess-
ment of causal association) is dependent on size of study
• Odds ratio cannot be converted into a positive predictive value for a given individual
3. Attributable fraction • See points 1–3 under Case-control approach
• Not possible to estimate results for a given individual or to combine results for multiple pathogens
4.  Quantification of  
pathogen load
• No diagnostic threshold established for most pathogens
Estimating etiology 
for pathogens not 
tested for
1. Ascribe “unknown” etiol-
ogy to cases negative for 
all tested pathogens
• Underestimated if specificity of pathogens tested for is <100% (unless accounting for this using an 
attributable fraction approach)
• Overestimated if sensitivity of pathogens tested for is <100%
Combining multiple 
test resultsa
1. Expert adjudication • Time-intensive to deliberate on each case to assign etiology
• Does not allow for quantification of uncertainty
• Preconceptions of experts may bias results
• Does not account for imperfect sensitivity
• Process results in an all-or-nothing decision about each pathogen(s)
2. Latent class analysis • Cannot incorporate control data
• Only feasible if the number of pathogens (classes) is constrained to a small number
• The researcher must “interpret” the measurement distribution profiles of each class and ascribe an 
etiology
a This can include performing >1 test for a given pathogen or from different pathogens identified in different specimens.
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example, if independent PCR assays for 30 different pathogens 
are undertaken, each with a specificity of 95%, a false-positive 
result is expected in 79% of cases, and multiple false positives 
in 45% of cases.
Approach to Challenge 2. A: Case-Control Odds Ratio Analysis
One approach to assess the role of detected pathogens in pneu-
monia cases is to compare their infection status (ie, laboratory 
test results) to people without pneumonia (ie, controls). The 
odds ratio (OR) describes the association between test results 
and pneumonia status. Conventionally, the OR is used to make 
a binary decision about a pathogen’s role: pathogens with ORs 
statistically significantly greater than 1 are considered asso-
ciated with case status and cases positive for these pathogens 
have their pneumonia etiology attributed to them, whereas 
pathogens not meeting this criterion are excluded as potential 
causes of pneumonia. This approach assumes 100% specificity 
among cases who test positive for a pathogen (ie, pneumonia is 
attributed to that pathogen if it is detected in a case, despite the 
fact that it may have also been detected in some controls). The 
magnitude of the OR does not have interpretive value about 
the fraction of the etiologic contribution to pneumonia, nor 
about the positive predictive value of a test in a given individ-
ual. Additionally, the OR approach cannot be applied to meas-
urements not available from controls (eg, induced sputum, lung 
aspirate, pleural fluid).
The use of control data in the assessment of pneumonia etiol-
ogy is illustrated by a recent Swedish study that assessed 15 viral 
Figure 1. Differences in pneumonia etiology by specimens, assays, and analytical approaches. Pneumonia etiology using results of blood culture testing (A); results of 
blood culture adjusted for sensitivity (B); results of nasopharyngeal (NP) polymerase chain reaction (PCR) for 7 viruses (C); results of NP PCR, limited to pathogens for which 
the case-control odds ratio was significantly greater than 1 (type 1 error = 0.05) (D); results of method D after applying attributable fraction (AF) adjustment (E); results of blood 
culture and NP PCR from cases only (F); results of blood culture and NP PCR, limited to pathogens for which the NP PCR case-control odds ratio was significantly greater than 
1 (type 1 error = 0.05) (G); results of method G after applying AF adjustment (H). Each “method” is a combination of the study design (case-only or case-control), analytical 
approach (raw results, adjustment for measurement error, odds ratio, AF), and assumed measurement error (ie, sensitivity and specificity) of the assay. The analyses were 
performed on a hypothetical study of 1000 pneumonia cases and 1000 controls (for case-control comparisons). The hatched slice represents a bacterial etiology (ie, cases 
positive by blood culture only); the black slice represents those with a mixed bacterial and viral etiology (ie, cases positive by blood culture and viral PCR); the solid gray 
slice represents viral etiology (ie, cases positive by viral PCR only). Abbreviations: ADENO, adenovirus; AF, attributable fraction; ECOL, Escherichia coli; ENFA, Enterococcus 
faecium; FLUA, influenza A; FLUB, influenza B; HBOV, human bocavirus; HINF, Haemophilus influenzae; HMPV, human metapneumovirus A/B; KPNE, Klebsiella pneumoniae; 
MCAT, Moraxella catarrhalis; N/A, not applicable; NMEN, Neisseria meningitidis; NP, nasopharyngeal; OR, odds ratio; PAER, Pseudomonas aeruginosa; PCR, polymerase 
chain reaction; PNEU, Streptococcus pneumoniae; RHINO, human rhinovirus; RSV, respiratory syncytial virus A/B; SASP, Salmonella species; SAUR, Staphylococcus aureus; 
Unk, unknown.
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pathogens by PCR in nasopharyngeal (NP) specimens [9]. At 
least 1 virus was detected in 77% of 93 cases with radiographic 
pneumonia. However, 56% of 220 matched controls also had 
viruses detected. In the adjusted OR analysis, only 3 viruses 
(influenza, human metapneumovirus [HMPV], and respiratory 
syncytial virus [RSV]) were statistically significantly positively 
associated with case status; the other pathogens assessed (eg, 
bocavirus, parainfluenza virus) were not associated or were 
negatively associated with case status and therefore no etiology 
was attributed to them.
Having an OR not significantly greater than 1 does not rule 
out the pathogen as a cause of pneumonia, however (ie, absence 
of evidence of an association is not equivalent to evidence 
of absence of an association). For example, pneumococcus 
commonly colonizes the nasopharynx of children with and 
without pneumonia; detection of this pathogen in the upper 
respiratory tract of controls at a similar or higher prevalence 
compared with cases does not mean pneumococcus is not a 
cause of pneumonia. An OR <1 may arise when the specimen 
being tested has poor specificity for detecting the cause of pneu-
monia, or it may reflect bias (eg, a consequence of antibiotics 
reducing the prevalence of bacteria among cases). Additionally, 
interaction between potential pathogens may create a situation 
in which a pathogen sometimes appears to have a protective 
effect (eg, by competitively inhibiting the growth of another 
causally relevant pathogen).
Accepting the analytic and interpretive constraints of the OR 
approach, there are also important design considerations for 
case-control studies. Perhaps most important is the selection 
of the control group [12, 13]; if it excludes certain segments of 
the population that give rise to cases, results are prone to bias. 
Sample size is another important consideration as small studies 
will be biased toward detecting significant associations only for 
very prevalent pathogens or those most strongly associated with 
case status.
Approach to Challenge 2. B: Attributable Fraction Analysis
The attributable fraction (AF) method addresses a limitation 
of the case-control OR approach—the assumption of 100% 
specificity among cases who test positive for a pathogen—
by accounting for the pathogen prevalence among controls. 
Although initially developed as a way to assess the fraction of 
disease attributed to exposure(s) in noncommunicable disease 
epidemiology, recently this method has been used to attrib-
ute etiology [7, 14, 15]. The proportion of cases infected with 
a given pathogen for whom that pathogen is deemed respon-
sible for their illness, ie, the “attributable fraction among the 
exposed” (AFE), is calculated as 1 – (1 / OR), where OR is the 
case-control odds ratio for that pathogen. Bruzzi et al proposed 
an extension of this method using multiple logistic regression 
to estimate the summary AF for multiple risk factors [16]; this 
approach has been applied in the field of diarrheal etiology to 
estimate the AF for a pathogen adjusted for other pathogens 
that are present [17].
Table 2 illustrates the calculation of the AFE and AF using 
case and control pathogen prevalences. For example, HMPV 
was detected in 8.2% of cases and 4.3% of controls, which yields 
an OR = 1.98 and AFE = 1 – (1 / 1.98) = 0.49 (ie, 49% of cases 
testing positive for HMPV are attributable to HMPV). The pop-
ulation AF for HMPV (ie, the proportion of all cases attributa-
ble to HMPV) is 4.1% (calculated as 49% AFE × 8.2% HMPV 
positive among cases).
The sum of all pathogen-specific AFs is not constrained to 
100%. As applied to risk factors, this means disease could have 
been prevented if any one of multiple causal exposures had 
been averted. When applied to infectious causes of pneumonia, 
Table  2. Calculation of the Attributable Fraction, the Fraction of Cases 
Attributed to Each of 7 Pathogens, in a Hypothetical Study of 1000 Cases 
With Pneumonia and 1000 Community Controls by Comparing Prevalence 





Controls, % OR (95% CI) AFE, % AF, %
Adenovirus 11.0 12.7 0.85 (.65–1.12) NA NA
Human  
bocavirus
14.8 14.7 1.01 (.79–1.30) 1.3 0.2
HMPV 8.2 4.3 1.98 (1.35–2.91) 49.5 4.1
Influenza A 3.1 0.9 3.40 (1.60–7.19) 70.6 2.2
Influenza B 1.3 0.6 2.18 (.82–5.75) 54.1 0.7
RSV 21.4 2.4 11.20 (7.21–17.41) 91.1 19.5
Human  
rhinovirus
20.8 20.5 1.02 (.82–1.27) 2.1 0.4
Any virus 61.8 43.9 27.1
Bolded numbers are statistically significant.
Abbreviations: AF, attributable fraction calculated as prevalence in cases × AFE; AFE, 
attributable fraction among the exposed calculated as 1 – 1 / odds ratio; CI, confidence 
interval; HMPV, human metapneumovirus A/B; NA, not applicable; OR, odds ratio; RSV, 
respiratory syncytial virus A/B.
Figure 2. Probability of 1 or more false-positive test results with increasing num-
ber of tests performed. Probability calculation based on binomial theorem [eg, prob-
ability ≥1 false positive = 1 – probability of zero false positives = 1– (specificitynumber 
of tests)]. In this example, specificity is set at 95%.
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if AFs sum to >100%, it is not clear if this indicates that pneu-
monia is definitely caused by >1 pathogen or reflects bias and 
confounding in estimating the OR. If AFs sum to <100% it may 
be because the sensitivity of the tests is usually not accounted 
for (ie, 100% sensitivity is assumed).
Although the AF approach improves on the OR approach by 
accounting for background (ie, control) prevalence, it has all of 
the other constraints of the OR approach: Pathogens with ORs 
not statistically significantly greater than 1 are excluded; sample 
size and pathogen prevalence influence which pathogens are 
statistically significant; it only applies to analyses involving a 
single measurement type for each pathogen; and it only applies 
to specimens collected from both cases and controls. Most 
pneumonia etiology studies violate these constraints; however, 
the AF approach is useful for other syndromes such as diarrhea 
where a single specimen type (eg, stool) can easily be collected 
in large numbers of both cases and controls [14].
Another limitation of the AF approach is that it does not 
inform on the etiology at an individual level; ie, we do not know 
which of the test-positive cases have “false-positive” measure-
ments that merely represent colonization, upper respiratory 
infection, or asymptomatic shedding after an acute infection, 
rather than the cause of the pneumonia. The option for estimat-
ing etiology for an individual case is to assign the group etiologic 
fraction for pathogens detected in that case, regardless of the 
findings for other pathogens detected. For example, a case that 
tested positive for pneumococcus as well as 3 other pathogens 
will be assigned the same probability of having pneumococcal 
pneumonia as a case that tested positive for pneumococcus 
only. Likewise, all children testing negative for pneumococcus 
will be assigned zero probability of pneumococcal pneumonia. 
Because attributable fraction does not estimate etiology at the 
individual case level, it is not possible to characterize the clini-
cal, demographic, radiographic, laboratory, and mortality find-
ings of cases likely attributed to certain pathogens.
Some of these limitations, as well as the different etiologic 
inferences resulting from different analytic approaches, are 
illustrated in Table 3 and Figure 1, methods C, D, and E. Case 
5 in the line list in Table 3 illustrates the challenge of interpret-
ing etiology using AFE for cases with multiple positive NP PCR 
measurements significantly associated with case status.
Approach to Challenge 2. C: Quantification of Pathogen Load
In the field of clinical microbiology, microbes detected in higher 
quantities are regarded as being more likely to be clinically sig-
nificant. An association between nasopharyngeal bacterial load 
and childhood pneumonia has been suggested, and pathogen 
density in respiratory specimens has been assessed as a measure 
to distinguish a pathogen as being causative of pneumonia [18–
21]. Higher mean or median density of pneumococcal DNA in 
the upper respiratory tract has been associated with pneumo-
coccal pneumonia in HIV-infected South African adults [18] 
and radiologically confirmed pneumonia in Vietnamese chil-
dren [19]. Higher median nasopharyngeal RSV or influenza 
virus density was found in those with lower respiratory tract 
infection compared with asymptomatic controls [20]. Despite 
these findings, most pneumonia studies have found substantial 
overlap in the density distribution of patients with pneumonia 
and those with milder or no illness [19, 20, 22, 23]. To date, no 
clear thresholds in pathogen density distinguish a pathogen as 
being causative of pneumonia; larger studies or more sophisti-
cated analytical methods may reveal greater interpretive value 
of density for some pathogens. Additionally, while applying a 
threshold may improve the specificity, it would result in a loss of 
sensitivity that would need to be quantified and accounted for.
Challenge 3: Etiology Due to Pathogens Not Tested For
Pneumonia may be caused by pathogens for which no testing 
was performed. How much this “none of the above” category 
contributes to the etiology assessment depends on how many 
Table  3. Integration of Hypothetical Individual Test Results From Pneumonia Cases With Blood Culture and Nasopharyngeal (NP) Polymerase Chain 
Reaction (PCR) Results, Accounting for Imperfect Specificity of NP PCR
Case Blood Culture NP PCR
NP PCR After Case- 
Control Analysisa
NP PCR After  
AFE Analysisb
Integration of Blood  
Culture and NP PCR
1 Streptococcus pneumoniae RSV RSV RSV*0.91 S. pneumoniae and RSV*0.91
2 Staphylococcus aureus Influenza A Influenza A Influenza A*0.71 S. aureus and influenza A*0.71
3 Haemophilus influenzae HMPV HMPV HMPV*0.50 H. influenzae and HMPV*0.50




Negative NA E. coli and K. pneumoniae
5 Negative Influenza A, RSV Influenza A, RSV Influenza A*0.71, RSV*0.91 Influenza A*0.71, RSV*0.91
6 Negative Human bocavirus, 
rhinovirus
Negative NA Negative
7 Negative Influenza B, RSV RSV RSV*0.91 RSV*0.91
8 Negative Negative Negative NA Negative
Abbreviations: HMPV, human metapneumovirus A/B; NA, not applicable; NP, nasopharyngeal; PCR, polymerase chain reaction; RSV, respiratory syncytial virus A/B.
aPathogens not significantly associated with case status (non–bold text; based on analysis presented in Table 2) are removed from consideration as a cause.
bFor each pathogen with an odds ratio >1.0 in the case-control analysis, the attributable fraction in the exposed from Table 2 is shown as a multiplier, which is interpreted at the individual 
level as the probability that the pneumonia is attributed to that pathogen without considering the other test results for that child.
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pathogens were tested for, the amount of evidence for those 
pathogens, and the sensitivity of their diagnostic measurements.
Approach to Challenge 3: Assign an “Unknown” Etiology
Most often, the proportion of cases with negative results for all 
tested pathogens is assigned as “unknown” etiology or, if an AF 
analysis is performed and the sum of the etiologies is <100%, 
the remaining etiologic fraction is attributed to “unknown” 
etiology. Because neither of these approaches accounts for the 
imperfect diagnostic sensitivity of the tests, the cases catego-
rized as “unknown” etiology would reflect cases with false-neg-
ative test results, as well as those with a pneumonia caused by 
pathogens not tested for. For example, the negative measure-
ments for case 8 in Table 3 could be consistent with a false-neg-
ative test result for pneumonia caused by a pathogen that was 
tested for, or with pneumonia caused by a pathogen not tested 
for, or with a diagnosis other than pneumonia. An approach 
that also accounts for measurement error would ensure that 
false-negative results did not contribute to the fraction of cases 
with “unknown” etiology.
Challenge 4: Combining Multiple Test Results
Combining results from >1 test or specimen type while simul-
taneously accounting for the sensitivity and specificity of each 
one poses an insurmountable challenge when estimating pneu-
monia etiology using the various methods described above. 
This is because the analytic methods adjust for measurement 
error for only one test at a time and only at the population level 
(ie, for the set of all cases). For cases that are test-positive for >1 
pathogen, we cannot determine whether one or both tests are 
false positive or if the case truly has pneumonia due to multiple 
etiologies. Consequently, we cannot estimate multiple etiologies 
at a population level.
This challenge can be illustrated by trying to combine hypo-
thetical blood culture results and nasopharyngeal PCR results 
for 7 respiratory viruses (Figure 1, methods F, G, and H). Most 
pneumonia cases have positive viral nasopharyngeal PCR 
results, with a smaller proportion being positive for bacteria by 
blood culture, yielding a large number of mixed infections with 
a variety of pathogen combinations. Testing additional speci-
mens (eg, induced sputum, serum) or targeting more patho-
gens would result in even more combinations. When using only 
case results, assuming 100% specificity and without attempting 
to adjust for diagnostic sensitivity of assays, combining bacte-
rial blood culture and viral nasopharyngeal PCR results is not 
technically difficult. However, displaying all of the pathogen 
combinations in a single graphical pie that describes the etiol-
ogy of pneumonia is visually incomprehensible. For simplicity, 
results can be categorized as bacterial (cases with only single 
or multiple bacteria found on blood culture), viral (cases with 
only single or multiple viruses detected by nasopharyngeal 
PCR), or mixed bacterial–viral infections (cases with bacteria 
detected in blood culture and 1 or more viruses detected by 
nasopharyngeal PCR).
The real challenge of combining results of multiple tests 
becomes apparent when attempting to account for the poor 
sensitivity of blood culture and the poor specificity of naso-
pharyngeal PCR measurements. It is not possible to simultane-
ously adjust for measurement error and integrate these adjusted 
measurements. For example, a child with a negative blood 
culture who tested positive for HMPV could have pneumonia 
caused by HMPV alone (if the blood culture was a true nega-
tive), both HMPV and bacteria (if the blood culture was a false 
negative, but would not know which bacterial species), bacteria 
only (if the HMPV was a false positive and the blood culture 
was a false negative; again, would not know which bacterial 
species), or something else entirely (true-negative blood culture 
and false-positive HPMV). Similarly, for cases with multiple 
positive results, we do not know if the pneumonia was caused 
by one of these pathogens, multiple pathogens, or other some-
thing else entirely (eg, cases 1–5, Table 3). For example, if a case 
tests positive for RSV and influenza A virus from nasopharyn-
geal PCR, with AFEs of 0.91 and 0.71, respectively, we cannot 
determine whether this particular child’s illness is caused by 
neither, one or both of these pathogens. This challenge becomes 
increasingly complex with the incorporation of additional path-
ogens, diagnostic tests and specimens.
Approach to Challenge 4. A: Expert Adjudication
Analytic integration of multiple positive results has been done 
using expert adjudication. Such adjudication can use computer 
algorithms programmed to follow rules set out by the researcher, 
or it can involve expert review of individual cases with standard 
clinical principles guiding the adjudication. This is similar to 
the approach clinicians take when caring for patients, but is not 
ideal for epidemiologic studies because it is time intensive, does 
not easily allow for quantification of uncertainty, and is sub-
ject to bias. Experts have preconceptions about causes of pneu-
monia and limited capacity for integrating multiple sources 
of information on etiology while also robustly accounting for 
measurement error in detecting causes of pneumonia.
Approach to Challenge 4. B: Latent Class Analysis
Latent class analysis (LCA) is a case-only statistical approach 
used to evaluate etiology when multiple measurements for a 
given pathogen are available, such as pneumococcus detected 
by blood culture, NP PCR, sputum culture, and lung aspirate 
culture [24, 25]. The “latent class” refers to the underlying true 
cause of the child’s pneumonia.
With LCA, cases are grouped into etiologic classes (the num-
ber of which must be prespecified by the researcher) based on 
their pattern of measurements, with cases in a class being more 
similar to one another with respect to those measurement pat-
terns than cases in other classes. The measurements usually 
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include a variety of imperfectly sensitive or specific tests (eg, 
culture of blood, PCR of upper respiratory tract specimens). 
A key assumption is that the measurements are independent of 
one another within a class. For each class, the analysis estimates 
the probability distribution of each measurement (eg, propor-
tion blood culture positive for pneumococcus within that class) 
and the proportion of cases attributed to that class. At the indi-
vidual level, cases have a probability of belonging to each class 
(eg, 20% in class A and 80% in class B).
LCA is best used to distribute cases into a limited number of 
clearly defined classes, such as the probability of being caused 
by Streptococcus pneumoniae or not. Because of computational 
limitations, LCA is not an option for evaluating large numbers 
of pathogens. LCA also does not determine the etiology for each 
class. Rather, the researcher must “interpret” the measurement 
distribution profiles of each class and ascribe a pathogen or a 
combination of pathogens as the etiology for each class.
Challenge 5: A Comprehensive Approach to Address All Challenges Above
The limitations of the existing analytic methods for etiologic 
analyses pose more of a challenge for pneumonia than for some 
other illnesses for several reasons. Because specimens are rarely 
available from the lung, multiple specimens from sites periph-
eral to the pneumonia infection are often tested, each contrib-
uting different kinds of information; only a subset of specimens 
are available from nonpneumonia control subjects. Often many 
pathogens are detected in the specimens (including specimens 
from controls without pneumonia) and some pathogens have 
more types of tests available than others. Depending on the 
specimens collected, pathogens targeted for detection, and 
analytic methods used, substantially different conclusions are 
drawn about pneumonia etiology between studies (Figure 1).
Approach to Challenge 5: Partial Latent Class Analysis
To address the limitations of existing analytic methods, the 
Pneumonia Etiology Research for Child Health (PERCH) 
study—a case-control study of pediatric pneumonia etiology in 
7 African and Asian countries—has developed a partial latent 
class, Bayesian approach (pLCA), to estimate pneumonia etiol-
ogy at the individual and population levels [26–28].
 The pLCA approach can integrate multiple types of measure-
ments, account for their respective sensitivity and specificity (by 
incorporating data from controls) at the pathogen level, accom-
modate a large number of pathogens, and estimate the propor-
tion of cases with an etiology due to pathogens not tested for. 
This method, while not solving all of the fundamental design 
issues of pneumonia etiology studies (eg, indirect observation 
of infection site, not all specimen types available from controls) 
and introducing other challenges (eg, the need for a prespec-
ified prior distribution for key parameters), addresses many 
of the limitations of the analytic methods described above. 
The approach can evaluate evidence for multiple-pathogen 
infections; estimating the likelihood of a given case of pneumo-
nia being caused by a single or multiple pathogens will be part 
of a future version of the pLCA.
CONCLUSIONS
Determining pneumonia etiology poses numerous analytical 
challenges. The imperfect diagnostic sensitivity and specificity 
of laboratory tests require that epidemiologists and researchers 
view laboratory results with a more critical eye, rather than tak-
ing them at face value, and explore new interpretive approaches. 
More advanced analytic techniques for cross-sectional data, such 
as the pLCA approach developed for the PERCH study, address 
many of the limitations of earlier approaches. However, even 
the pLCA approach cannot overcome some of the fundamental 
limitations of the current state of pneumonia etiology research: 
tests have measurement error, the ideal number of pathogens to 
test for is unknown, and most importantly, the specimens used 
to determine pneumonia etiology are generally not from the 
lung. Ultimately, a better understanding of pneumonia etiology 
will likely come from using advanced, integrated analytic tech-
niques, such as pLCA, on cross-sectional pneumonia studies, 
complemented by other designs that employ different angles of 
approach to the etiology question, such as longitudinal cohorts, 
vaccine probes, and postmortem and lung aspirate studies.
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